International Health News

A cure for MALT lymphoma?

DRESDEN, GERMANY. MALT lymphoma is a cancer of the mucosa-associated lymphoid tissue (the tissue responsible for the production of lymphocytes and antibodies) and is most often located in the gastrointestinal tract, particularly in the stomach. More than 90 per cent of all gastric MALT lymphomas are found in patients suffering from chronic Helicobacter pylori-associated inflammation of the stomach lining (gastritis). Researchers at the Technical University of Dresden now report that gastric MALT lymphomas can be put into remission by eradicating the underlying H. pylori infection. Their clinical trial involved 50 patients with confirmed low-grade gastric MALT lymphoma. The patients were treated for two weeks with amoxycillin, 750 mg three times daily and omeprazole (Losec), 40 mg three times daily. This cured the H. pylori infection in 48 of the 50 patients. The two remaining patients were treated for an additional week with 800 mg/day of metronidazole, 500 mg/day of clarythromycin and 40 mg/day of omeprazole. After this all 50 patients had been cured of their infection. Examination of biopsy specimens taken periodically after the completion of the treatment showed that 80 per cent of the patients achieved a complete remission of their MALT lymphoma within an average period of six months, four patients experienced partial remission and six showed no improvement. Among the 40 patients who had shown complete remission four relapsed within six to sixteen months. No relapses were observed in patients once they had passed the 16-month (500 days) mark and nine patients have now been followed for more than two years without relapse. The researchers conclude that eradication of the underlying H. pylori infection in MALT lymphoma patients can produce long-lasting remissions and possibly a complete cure.
Neubauer, Andreas, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. Journal of the National Cancer Institute, Vol. 89, September 17, 1997, pp. 1350- 55

category search
Keyword Search

My favourite Supplements

copyright notice